Table 1.
Response and resection rates from trials with first-line chemo/biologic therapy
| Study | Selection | Treatment | Response | Resection |
| Van Cutsem et al[88] 2009 | Unselected | Bevacizumab + chemotherapy (FOLFOX/FOLFIRI) | NA | 11.8% |
| 6% (R0) | ||||
| Okines et al[89] 2009 | Unselected | Bevacizumab + Oxaliplatin-based chemotherapy | 38% | 6.3% |
| Wong et al[90] 2011 | Unselected | Bevacizumab + XELOX | 68% | 48.0% |
| Loupakis et al[91] 2013 | Unselected | Bevacizumab + FOLFOXIRI | 64% | 15.0% |
| Martin et al[92] 2014 | Unselected | Bevacizumab + FOLFOX + DEBIRI | 78% | 35.0% |
| Bokemeyer et al[94] 2009 | KRAS WT | Cetuximab + FOLFOX | 57% | 7.3% |
| 4.7 (R0) | ||||
| Van Cutsem et al[95] 2011 | KRAS WT | Cetuximab + FOLFIRI | 57% | 16.0% |
| 7% (R0) | ||||
| Folprecht et al[22] 2010 | KRAS WT | Cetuximab + chemotherapy (FOLFOX/FOLFIRI) | 68% | 43.0% |
| 34% (R0) | ||||
| Garufi et al[96] 2010 | KRAS WT | Cetuximab + FOLFOXIRI | 79% | 60.0% |
| Ye et al[97] 2013 | KRAS WT | Cetuximab + FOLFOXIRI | 57% | 25% (R0) |
| Köhne et al[100] 2012 | KRAS WT | Panitumumab + FOLFIRI | 56% | 15.0% |
| Douillard et al[101] 2010 | KRAS WT | Panitumumab + FOLFOX | 57% | 27.0% |
| 5.2% (R0) | ||||
| NRAS WT | Panitumumab + FOLFOX | 31.0% |
NA: Not available.